TSH Biopharm (ROCO:8432) Cyclically Adjusted PS Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:8432 TSH Biopharm Corp Ltd ROCO:8432
91 GF Score
Price NT$50.60
GF Value NT$68.74
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is TSH Biopharm Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


TSH Biopharm  (ROCO:8432) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


TSH Biopharm Cyclically Adjusted PS Ratio Related Terms


TSH Biopharm Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for TSH Biopharm's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TSH Biopharm Cyclically Adjusted PS Ratio Chart

TSH Biopharm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.91 2.95 3.01 3.38 2.89

TSH Biopharm Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.54 2.66 2.90 2.44 2.37

ROCO:8432 vs ZTS: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, TSH Biopharm's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TSH Biopharm Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TSH Biopharm's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where TSH Biopharm's Cyclically Adjusted PS Ratio falls into.


ROCO:8432
91GF Score
TSH Biopharm Corp Ltd ROCO:8432
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TSH Biopharm Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

TSH Biopharm's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, TSH Biopharm's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=8.607/333.9520*333.9520
=8.607

Current CPI (Jun. 2026) = 333.9520.

TSH Biopharm Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 2.684 241.428 3.713
201612 3.390 241.432 4.689
201703 2.963 243.801 4.059
201706 3.312 244.955 4.515
201709 3.268 246.819 4.422
201712 3.112 246.524 4.216
201803 3.879 249.554 5.191
201806 3.682 251.989 4.880
201809 2.901 252.439 3.838
201812 2.961 251.233 3.936
201903 3.563 254.202 4.681
201906 3.126 256.143 4.076
201909 3.420 256.759 4.448
201912 3.104 256.974 4.034
202003 3.435 258.115 4.444
202006 2.363 257.797 3.061
202009 2.610 260.280 3.349
202012 3.248 260.474 4.164
202103 2.648 264.877 3.339
202106 2.741 271.696 3.369
202109 2.574 274.310 3.134
202112 2.799 278.802 3.353
202203 3.134 287.504 3.640
202206 2.854 296.311 3.217
202209 2.920 296.808 3.285
202212 3.168 296.797 3.565
202303 3.770 301.836 4.171
202306 4.433 305.109 4.852
202309 7.015 307.789 7.611
202312 11.526 306.746 12.548
202403 5.217 312.332 5.578
202406 6.132 314.175 6.518
202409 10.107 315.301 10.705
202412 7.581 315.605 8.022
202503 7.469 319.799 7.800
202506 7.007 322.561 7.254
202509 11.005 324.800 11.315
202512 9.293 324.054 9.577
202603 7.430 330.213 7.514
202606 8.607 333.952 8.607

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is TSH Biopharm (ROCO:8432) Overvalued in 2026?

Based on GuruFocus' analysis, TSH Biopharm stock appears to be undervalued. The current stock price of NT$50.60 is trading 26.4% below its estimated GF Value™ of NT$68.74. GuruFocus considers TSH Biopharm to be Modestly Undervalued.

Key valuation signals for ROCO:8432:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: NT$68.74 vs. price of NT$50.60 (26.4% below fair value)
  • GF Score™: 91/100 with 2 warning signs

No single metric tells the full story. See the ROCO:8432 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


TSH Biopharm Business Description

Address No.3-1, Park Street, 3rd Floor-1, Nangang District, Taipei, TWN, 115
TSH Biopharm Corp Ltd is engaged in sale of a variety of pharmaceuticals, chemical drugs and engaged in biotechnology services. The company specializes in the development, manufacture, and marketing of branded drugs for chronic diseases. Key therapeutic areas include cardiovascular, central nervous system, gastroenterology, and severe chronic diseases, alongside precision medicine/genetic testing services .The Company's revenue is earned domestically. It earns majority of its revenue from the sale of Lozenges.
91GF Score

Get the complete analysis for ROCO:8432

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$50.60
Price
NT$68.74
GF Value